Natural Alternatives International (NAII) and Actelion (ALIOF) Financial Review

Natural Alternatives International (NASDAQ:NAII) and Actelion (OTCMKTS:ALIOF) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.

Risk & Volatility

Natural Alternatives International has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Actelion has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.



Analyst Ratings

This is a breakdown of current ratings and recommmendations for Natural Alternatives International and Actelion, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natural Alternatives International 0 0 0 0 N/A
Actelion 0 0 0 0 N/A

Profitability

This table compares Natural Alternatives International and Actelion’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Natural Alternatives International 6.74% 13.63% 10.64%
Actelion N/A N/A N/A

Valuation & Earnings

This table compares Natural Alternatives International and Actelion’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Natural Alternatives International $132.44 million 0.64 $5.05 million N/A N/A
Actelion $2.46 billion 0.00 $707.04 million N/A N/A

Actelion has higher revenue and earnings than Natural Alternatives International.

Insider & Institutional Ownership

31.9% of Natural Alternatives International shares are owned by institutional investors. 28.0% of Natural Alternatives International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Natural Alternatives International beats Actelion on 5 of the 8 factors compared between the two stocks.

Natural Alternatives International Company Profile

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. It operates through two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. The company offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It also provides strategic partnering services, such as customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, packaging and delivery system design, and regulatory review. In addition, the company sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. The company's private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.

Actelion Company Profile

Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.

Receive News & Ratings for Natural Alternatives International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natural Alternatives International and related companies with MarketBeat.com's FREE daily email newsletter.